Siegfried Holding AG Stock Deutsche Boerse AG

Equities

SQG

CH0014284498

Pharmaceuticals

Market Closed - Deutsche Boerse AG 07:30:29 2019-06-28 EDT 5-day change 1st Jan Change
305 EUR +0.83% Intraday chart for Siegfried Holding AG -.--% -.--%

Financials

Sales 2024 * 1.3B 1.45B 1.35B 2B Sales 2025 * 1.42B 1.58B 1.47B 2.18B Capitalization 3.91B 4.36B 4.05B 6B
Net income 2024 * 147M 164M 152M 225M Net income 2025 * 171M 190M 177M 262M EV / Sales 2024 * 3.28 x
Net Debt 2024 * 355M 395M 368M 544M Net Debt 2025 * 310M 345M 321M 476M EV / Sales 2025 * 2.98 x
P/E ratio 2024 *
26.5 x
P/E ratio 2025 *
22.9 x
Employees 3,945
Yield 2024 *
0.42%
Yield 2025 *
0.44%
Free-Float 87.68%
More Fundamentals * Assessed data
Dynamic Chart
5 years
301.00
Extreme 301
323.00
10 years
113.32
Extreme 113.315
412.50
More quotes
Managers TitleAgeSince
Chief Executive Officer 53 17-04-30
Chief Tech/Sci/R&D Officer 56 19-03-31
Corporate Officer/Principal - 14-01-31
Members of the board TitleAgeSince
Director/Board Member 55 15-12-31
Director/Board Member 63 13-12-31
Chairman 61 09-12-31
More insiders
Siegfried Holding AG is a Switzerland-based life sciences company which is active in primary and secondary drug manufacturing. The Company produces both drug substances and drug products. The drug substance portfolio includes contract development and manufacturing of both active pharmaceutical ingredients (APIs) and intermediates. The drug products portfolio comprises licensing and contract or co-development and manufacturing of oral solids and sterile. The Company's products and substances are developed for treatment of hypertension, benign prostate hyperplasia, depression, chronic myeloid leukemia, glaucoma, asthma, schizophrenia and bipolar disorders and diabetes. The Company operates production facilities in Switzerland, Germany, France, Malta, the United States, China, and Spain.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
912 CHF
Average target price
1,016 CHF
Spread / Average Target
+11.39%
Consensus